OPTIMIZERX CORP
OPRXNASDAQTrading Snapshot
- Day Range
- $973.66 – $998.51
- 52-Week Range
- $4.54 – $22.25
- Volume
- $2.93B
- Avg Volume
- $3.03B
- Shares Outstanding
- 18.8M
- Next Earnings
- Nov 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $109M
- Last Q Revenue
- $21M
- P/E Ratio
- 32.9
- P/S Ratio
- 1.5x
- EPS (TTM)
- $0.24
- Dividend Yield
- —
- Dilution (1yr)
- +5.2%
Why Investors Own OPRX
- ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OPTIMIZERX CORP
OPRX
StockOtter · stockotter.spaceAbout OPTIMIZERX CORP
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) a
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook
OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-marg
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strengt
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow New functionality helps DSPs and agency planners create deterministic HCP and consumer au
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare profes